Moxifloxacin-induced arthropathy [3]

International Journal of Tuberculosis and Lung Disease

Volumn 11, Issue 1, 2007, Pages 117-

  Wong, H Y ^a   Chau, C H ^a   Yew, W W ^a  

^a GRANTHAM HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ARTHROPATHY; BLOOD TESTIS BARRIER; BONE LESION; BONE RADIOGRAPHY; CENTRAL NERVOUS SYSTEM DISEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; HUMAN; LETTER; LIVER TOXICITY; LUNG TUBERCULOSIS; MUSCULOSKELETAL DISEASE; MYCOBACTERIUM TUBERCULOSIS; PAIN; PHOTOTOXICITY; PRIORITY JOURNAL; QT PROLONGATION; SPUTUM EXAMINATION; SWELLING; VISUAL ACUITY;

AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; ARTHRITIS; AZA COMPOUNDS; DRUG THERAPY, COMBINATION; HUMANS; ISONIAZID; MALE; PYRAZINAMIDE; QUINOLINES; RIFAMPIN; TUBERCULOSIS, PULMONARY;

EID: 33846242528     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Gillespie S H, Billington O. Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother 1999; 44: 393-395.
2. Codecasa L R, Ferrara G, Ferrarese M, et al. Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs. Respir Med 2006; 100: 1566-1572.
3. Balfour J A, Lamb H M. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs 2000; 59: 115-139.
4. Stahlmann R, Lode H. Toxicity of quinolones. Drugs 1999; 58 (Suppl 2): 37-42.
5. Von Keutz E, Schluter G. Preclinical safety evaluation of moxifloxacin, a novel fluoroquinolone. J Antimicrob Chemother 1999; 43 (Suppl B): 91-100.